Padmanee Sharma

Padmanee Sharma

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Padmanee Sharma

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Cell
Verified
Journal Article
Closed access
PSPadmanee Sharma
Padmanee Sharma
SHSiwen Hu-Lieskovan
Siwen Hu-Lieskovan
JWJennifer A. Wargo
Jennifer A. Wargo
ARAntoni Ribas
Antoni Ribas

5 November 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RMRobert Motzer
Robert Motzer
BEBernard Escudier
Bernard Escudier
DMDavid F. McDermott
David F. McDermott
SGSaby George
Saby George
HHHans J. Hammers
Hans J. Hammers
PSPadmanee Sharma
Padmanee Sharma
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.)

5 January 2018 in Science
Verified
Journal Article
Closed access
PDF file
VGVancheswaran Gopalakrishnan
Vancheswaran Gopalakrishnan
CSC. N. Spencer
C. N. Spencer
LNLuigi Nezi
Luigi Nezi
Alexandre ReubenAlexandre Reuben
Alexandre Reuben
MAMiles C. Andrews
Miles C. Andrews
JWJennifer A. Wargo
Jennifer A. Wargo
Good bacteria help fight cancer: Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32

3 April 2015 in Science
Verified
Journal Article
Closed access
PDF file
PSPadmanee Sharma
Padmanee Sharma
JAJames P. Allison
James P. Allison
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.


1 March 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
PSPadmanee Sharma
Padmanee Sharma
MRMargitta Retz
Margitta Retz
ASArlene Siefker-Radtke
Arlene Siefker-Radtke
ABAri Baron
Ari Baron
Andrea NecchiAndrea Necchi
Andrea Necchi
MGMatthew D Galsky
Matthew D Galsky